Analyzing Humacyte (NASDAQ:HUMA) and United Therapeutics (NASDAQ:UTHR)

United Therapeutics (NASDAQ:UTHR) and Humacyte (NASDAQ:HUMA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Insider & Institutional Ownership

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares United Therapeutics and Humacyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Humacyte	-4,556.29%	-983.32%	-88.84%

Risk & Volatility

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for United Therapeutics and Humacyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1	2	11	0	2.71
Humacyte	1	0	7	0	2.75

United Therapeutics presently has a consensus target price of $621.00, indicating a potential upside of 14.66%. Humacyte has a consensus target price of $6.54, indicating a potential upside of 1,268.55%. Given Humacyte’s stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than United Therapeutics.

Earnings and Valuation

This table compares United Therapeutics and Humacyte”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18 billion	7.30	$1.33 billion	$27.95	19.38
Humacyte	$2.04 million	65.09	-$40.83 million	($0.49)	-0.98

United Therapeutics has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

United Therapeutics beats Humacyte on 10 of the 14 factors compared between the two stocks.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.